Key points are not available for this paper at this time.
The DEFINITIVE LE study demonstrated that DA is a safe and effective treatment modality at 12 months for a diverse patient population with either claudication or CLI. Furthermore, DA was shown to be noninferior for treating PAD in patients with diabetes compared with those without diabetes. (Study of SilverHawk/TurboHawk in Lower Extremity Vessels DEFINITIVE LE; NCT00883246).
McKinsey et al. (Fri,) studied this question.